Dedicated to developing treatments for serious eye disorders, EyePoint Pharmaceuticals’ (NASDAQ: EYPT) pipeline includes a proprietary technology for sustained intraocular drug delivery known as Durasert. The technology supports the use of EYP-1901, an investigational sustained delivery intravitreal anti-VEGF treatment initially targeting wet age-related macular degeneration, which can cause severe vision problems. To learn more about […]
